Skip to content

Evaluate Safety & Efficacy of Condroflex in Subjects With OA

Phase 3 Study, to Evaluate Safety & Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00838487
Acronym
ZD20108
Enrollment
240
Registered
2009-02-06
Start date
2009-03-31
Completion date
2010-03-31
Last updated
2009-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly, Osteoarthritis, Treatment

Keywords

chondroitin, glucosamine, osteoarthritis

Brief summary

Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities Arthritis Index), achieved with Condroflex ® oral administration(sulfate glucosamine + chondroitin sulfate sodium) in association with therapeutic exercises, compared to placebo in association with therapeutic exercises in individuals with knee OA and not exposed to prior treatment with the products under investigation.

Detailed description

To have osteoarthritis degree 2 or 3 / To be capable to consent

Interventions

OTHERcondroflex and exercise

1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week

OTHERsugar pill and exercise

1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week

Sponsors

Zodiac Produtos Farmaceuticos S.A.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* to have knee osteoarthritis degree 2 or 3 * to be capable to consent

Exclusion criteria

* previous drug treatment * concomitant diseases * concomitant drugs

Design outcomes

Primary

MeasureTime frame
improvement of pain12 week

Secondary

MeasureTime frame
rigidity restriction12 week

Countries

Brazil

Contacts

Primary ContactSuely Roizenblatt
suelyroi@gmail.com55 11 5908-7081
Backup ContactMagda Bignotto
magda@afip.com.br55 11 5908-7081

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026